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Summary. Transcription factors encoded by PAX3 and
PAX7 are amongst the first expressed in the embryo,
being principal regulators of neurogenic and myogenic
progenitor cell specification and embryonic
segmentation. The basis for this review lies in the
supposition that genetic programs for cell migration,
thought regulated by PAX3 and PAX7 during embryonic
development, become tools used by the metastatic cell.
In highly metastatic neoplasms arising from cells of
neurogenic and myogenic lineages such as embryonal
rhabdomyosarcoma and cutaneous malignant melanoma,
markedly high expression levels of PAX3 and PAX7
support this supposition.
As PAX3 and PAX7 are known to play a role in the
regulation of migratory events in embryogenesis, it is
possible that the metastatic potential of these tumours is
directly linked to migratory properties conferred them
through PAX expression.
Here we provide a novel perspective by correlating
metastasis with expression of PAX3, PAX7 and
ephrin/Eph receptors as well as NCAMs, cell surface
markers normally involved in migration and adhesion
during development, and propose a role for PAX genes in
the increased metastatic potential of these tumours.
Key words: Developmental genes, Metastasis, Pax
genes, NCAM and ephrins
Introduction: Scope of the review
Ultimately, it is the metastatic tumour cell that
proves most dangerous to the cancer sufferer. The
horrifying implications that metastatic spread has on the
prognosis for a cancer victim, compels study into the
phenotype of the metastatic tumour cell; presumably, a
greater understanding of this phenotype will lead to
improved treatment regimes. 
It is known that approximately 1 in 10,000
metastatic cells survive and only those disseminated
cells that express the correct combination of gene
products will successfully metastasise. Furthermore,
metastatic cells endure a process of events similar to
those that occur in development of the embryo,
specifically, delamination, migration through tissues and
adhesion at secondary sites. Both embryonic and
metastatic cells undergo these processes while in a
relatively undifferentiated state. 
The supposition that genetic programs regulating
migration during embryonic development become tools
of survival for the metastatic cell forms the basis for this
review. In particular, cell, surface molecules known to
provide migratory and adhesive properties to cells within
the embryo are examined for their ability to increase the
metastatic potential of cells within neoplasms.
Genes that play a role in early embryonic patterning,
such as the Hox and Pax developmental genes, are key
factors in cell differentiation and migration. Here we
specifically review the role of PAX3 and PAX7 in
regulation of cell surface molecules involved in the
migratory process. 
Moreover, the relationship between PAX genes and
cell surface molecules such as Eph receptors, ephrins
and NCAM will be examined in two neoplasms having a
highly metastatic phenotype, embryonal rhabdomyo-
sarcoma (ERMS) and cutaneous malignant melanoma
(CMM). 
Observations that PAX3 and PAX7 have been found
over-expressed in ERMS, while PAX3 is over-expressed
in CMM, have led to the suggestion that increased PAX
expression leads to up-regulation of key cell surface
molecules, thereby conferring migratory properties to
neoplasms which influence their metastatic potential. We
predict that such information will provide valuable
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Rhabdomyosarcoma is a soft tissue sarcoma arising
from rhabdomyoblasts (a primitive skeletal muscle cell
with eosinophilic cytoplasm). There are two subtypes of
rhabdomyosarcoma – alveolar (ARMS) and embryonal
(ERMS); the embryonal form is the most common,
presenting in 70-80% of cases (Bridge et al., 2002).
Within the tumour, cells are committed to a myogenic
lineage but arrested prior to terminal differentiation
(Astolfi et al., 2001). The presence of rhabdomyoblasts
suggests that the tumours originate from the same
embryonal mesenchymal stem cells as striated skeletal
muscle cells. 
Cytogenetics
Although cytogenetic studies reveal no specific
chromosomal aberration for ERMS, a hyperdiploid
karyotype is a persistent feature (Polito et al., 1999;
Middel et al., 2000; Bridge et al., 2002); one study
revealed cells containing 100 chromosomes (Olegard et
al., 1992). Hyperdiploid states reported thus far show
gains of chromosomes 2, 7, 8, 11, 12, 13 and 20. Within
the hyperdiploid karyotype chromosomal losses can
occur; chromosome losses reported to date include
chromosomes 1, 6, 10, 14, 15 and 16 (Polito et al.,
1999). 
Prognosis
ERMS is the most common soft-tissue sarcoma of
childhood affecting children between the ages of 2-19
years. The prognosis for ERMS depends largely on the
site affected. ERMS that arise in the orbit/eyelid,
parameninges, bladder or prostate, have a better
prognosis (3-year survival rate of 72%, Baker et al.,
2000) than those arising in the CNS, for which the
prognosis is extremely poor with survival beyond 24
months being rare (Celli et al., 1998). 
The most frequent sites in which secondaries arise
are the regional lymph nodes, lungs, liver, bone marrow,
bones, and brain (Altman and Schwartz, 1983) with 83%
of metastases becoming manifest within one year of
diagnosis.
The high expression levels of PAX genes within
ERMS may be linked to the observed increase in
expression of important cell migratory molecules,
NCAM and more significantly, polysialylated NCAM
(PSA-NCAM) (Phimister et al., 1994; Gluer et al.,
1998a,b). The ability of PAX genes to confer a high
metastatic potential to ERMS cells via up-regulation of




Cutaneous malignant melanoma (CMM) is a highly
metastatic tumour arising from cutaneous intraepidermal
melanocytes. In normal development, melanocytes
originate from neural crest cells, a unique population of
embryonic stem cells that arise along the lateral aspects
of the neural folds. During embryonic neurulation, crest
cells detach and migrate to target locations where they
undergo terminal differentiation.
Cells that give rise to CMM usually progress from a
pre-existing melanocytic nevus (congregations of benign
melanocytes located in the epidermis and/or dermis)
(Zhao et al., 2002). Although there are genetic
influences associated with an increased risk of
developing melanoma, the increased incidence of
melanoma in recent generations has been directly linked
to the independent risk factor of excessive sun exposure.
It is believed that an initial high dose of ultraviolet
radiation causes substantial damage to the melanocyte,
resulting in mutations that disrupt the DNA without
subsequent apoptosis (Gilcrest et al., 1999). 
Cytogenetics
Although the main cause of CMM is thought due to
ultraviolet radiation, 10% of CMM cases are familial
(Fountain et al., 1990). An inherited syndrome thought
to increase susceptibility to CMM, is Dysplastic Nevus
Syndrome (DNS), an autosomal dominant inherited
disposition with patients possessing 10-100 large nevi or
moles (Greene et al., 1985; Bale et al., 1986).
To date, the two principal loci known to be
associated with familial inheritance of CMM are at 1p
(CMM1) and 9p (CMM2). Through multipoint linkage
analysis, Bale et al. (1989) mapped CMM1 to 1p36. The
locus denoted CMM2, at 9p21, contains several genes
considered as candidates for involvement in CMM (Puig
et al., 1995). While CMM1 is involved in the early
stages of CMM, tumour suppressor genes at 9p are
thought involved in the pre-disposition and progression
of CMM (Puig et al., 1995). There is also thought to be a
third locus for CMM on chromosome 6 (Dracopoli et al.,
1987). 
Prognosis
Early stage melanomas are highly curable by
complete surgical excision resulting in a greater than
95% eight-year survival rate. However, if lymph node
metastases are present, the 5-year survival of patients is
between 30% and 50% (Zettersten et al., 2002). 
Progression of CMM is thought linked to changes in
expression of cell surface molecules involved in the
migration of neural crest progenitor cells. Several studies
of CMM have shown dramatic changes in expression
patterns of NCAM isoforms (Mooy et al., 1995; Reed et
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al., 1999) as well as Eph receptors and ephrins (Easty et
al., 1997, 1999; Bittner et al., 2000; Easty and Bennett,
2000; McArdle et al., 2001). 
In this paper we explore the possible link between
the cellular origins of ERMS and CMM and their high
metastatic potential. These tumours arise from
mesenchymal and neural crest cell lineages,
respectively; during development both express PAX3 and
PAX7 and are characterised as migratory. Since recent
evidence suggests that PAX genes regulate expression of
cell surface molecules important in migration, we
discuss the possibility that metastatic potential is
associated with continued, increased or altered PAX gene
expression in tumours. 
PAX3 and PAX7 genes
Structure
The PAX family of genes derive their name from the
paired box which consists of a 384 bp DNA sequence
encoding a highly conserved DNA binding domain
(Burri et al., 1989; Krauss et al., 1991). The nine
members of the gene family are further classified into
groups (I-IV) according to possession of a full or partial
homeodomain, a DNA binding domain also found in
homeobox genes (Bopp et al., 1986). Furthermore, PAX
genes may contain a conserved octapeptide region (Burri
et al., 1989) thought to participate in methylation of the
genes (Ziman and Kay, 1998) (Fig. 1). 
Both Group III genes, PAX3 (2q35, Ishikiriyama,
1993) and PAX7 (1p35-1p36.2, Schäfer and Mattei,
1993) are very similar in structure; both genes encode
the paired box in exons 2-4, the homeobox in exons 5-6
and the transactivation domain in exons 6-8 (Jostes et
al., 1990; Vorobyov et al., 1997). The paired box is the
most similar in sequence, bar a few differences in the
region encoding the carboxyl end of the paired domain
(Jostes et al., 1990). 
The functions of PAX3 and PAX7 in embryogenesis
All PAX genes encode a family of transcription
factors that function in the highly specific, spatio-
temporal regionalisation of the embryo (for review see
Gruss and Walther, 1992; Chalepakis et al., 1993;
Mansouri et al., 1994). Pax3 and Pax7 are amongst the
earliest transcription factors present during
embryogenesis (Jostes et al., 1990; Goulding et al.,
1991; Mansouri et al., 1996). Within the neural tube,
where they play a role in dorso-ventral patterning, both
genes are expressed in cells that specify dorsal neurons
(Jostes et al., 1990; Goulding et al., 1991). Their
expression patterns in the developing brain correlate
with subdivision and specification of brain regions
(Stoykova and Gruss, 1994). In particular, expression
has been detected laterally in the alar plate of the
mesencephalon (midbrain) and in the ventricular zone
and mantle layer of the tectum. In the mesencephalon
Pax7 expression is associated specifically with
differentiation of the tectum as well as formation of its
laminar structure, being expressed in neuronal cells that
migrate toward the most dorsal layer, the stratum
griseum superficiale (Kawakami et al., 1997). 
Pax3 and Pax7 also function in specification and
migration of neural crest derived cells; Pax3 is involved
in the migration and terminal differentiation of
melanocytes and Schwann cells (Kioussi et al., 1995)
whereas Pax7 is involved in development of cranio-
facial structures (Mansouri et al., 1996).
Finally, Pax3 and Pax7 are expressed in myogenic
precursor cells and play a role in the migration of these
cells from the somatic dermamyotome to the limb buds
during myogenesis (Jostes et al., 1990; Kawakami et al.,
1997; Tremblay et al., 1998; Henderson et al., 1999;
Swartz et al., 2001). Both genes are expressed prior to
MyoD expression and it is believed that both factors are
down-regulated upon terminal differentiation of the cells
into skeletal muscle cells (Williams and Ordahl, 1994;
Marcelle et al., 1995). The life-long persistent
expression of Pax7 in satellite cells (a population of
myogenic stem cells) is believed responsible for
maintenance of the satellite cells in an undifferentiated
state (Seale et al., 2000).
The importance of Pax genes in specification and
migration of neural, neural crest and myogenic cell
lineages is highlighted by the mutated phenotype.
Mutations in PAX3 result in Waardenburg syndrome
(Hoth et al., 1993; Tassabehji et al., 1993), characterised
by hearing loss as well as pigmentation abnormalities
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Fig. 1. Pax3 and Pax7 contain a paired DNA domain domain consisting
of amino- and carboxy-terminal subdomains, each of which is composed
of three helices in a helix-turn-helix motif. The third helix of each
subdomain is shown in contact with the DNA. The Pax proteins also
contain an octapeptide followed by a homeodomain containing an
addit ional helix-turn-helix DNA binding domain. Finally, the
transactivation domain is indicated. 
due to the absence of melanocytes. 
The Pax3 mutant, Splotch mouse (the term ‘Splotch’
refers to coat colour abnormalities resulting from
melanocytic defects) exhibits severe defects in the
formation and migration of myoblasts (Franz, 1990),
neural crest derived Schwann cells, dorsal root and
cranial ganglia and melanocytes (Epstein et al., 1991). 
Pax7-/- mice may develop to term; however, they are
characterised by growth retardation, severe defects to the
maxilla and nasal structures (Mansouri et al., 1996) and
small musculature due to a complete lack of muscle
satellite cells (Seale et al., 2000). 
Pax3 and Pax7 transcripts
Functional diversity of Pax3 and Pax7 genes in vivo
is thought linked to the ability to produce alternately
spliced gene products that alter the structure and
consequently the binding activity of the paired and
homeodomain regions (Tsukamoto et al., 1994;
Underhill and Gros, 1997; Seo et al., 1998; Ziman and
Kay, 1998). The resultant isoforms encoded by alternate
Pax transcripts are postulated to bind to a variety of
target gene sequences, by alternate use of the paired
domain, the homeodomain or both, thus activating a
variety of downstream pathways (Underhill and Gros,
1997; Vogan and Gros, 1997) (Fig. 2). 
Originally both PAX3 and PAX7 genes were thought
to contain only eight exons. It is now known that the
coding region of PAX3 consists of ten exons (Barber et
al., 1999) and the coding region of PAX7 consists of nine
or more exons (Barr et al., 1999). 
Recent studies show that PAX3/Pax3 may be
alternately spliced at exons 4, 5, 8, and 9 to produce six
different transcripts (Barber et al., 1999) including
transcripts that lack an entire homeodomain (Tsukamoto
et al., 1994) (Fig. 3). These alternate PAX3 transcripts
encode proteins with different binding and
transactivation activities having an important effect on
the functional role of the gene (Underhill and Gros,
1997)
Four distinct Pax7 transcripts that contain structural
differences in the paired box have been described
previously (Ziman et al., 1997; Ziman and Kay, 1998;
Kay and Ziman, 1999). These transcripts are expressed
in a cell/tissue specific manner, and are thought to play a
role in differentiation of cells along neurogenic and
myogenic lineages (Ziman and Kay, 1998; Ziman et al.,
2001). Novel transcripts of PAX7 that contain an
additional ninth exon have been found expressed in
human tumour tissue (Barr et al., 1999) and in vertebrate
species such as the zebrafish (Seo et al., 1998). Whether
transcripts containing the ninth exon are expressed in
normal human tissue is at present unknown and currently
under investigation. Changes at the 3’ end of the gene
are likely to affect the activity of the transactivation
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Fig. 2. A schematic diagram indicating possible modes of binding by
alternate Pax3 or Pax7 isoforms to target DNA. Alternate Pax isoforms
are produced by alternate splicing at intron-exon boundaries during
transcription of the Pax3 or Pax7 genes. 1) Pax protein binding to target
DNA using both the paired and homeodomains. 2) Pax protein binding
to target DNA using either the paired domain or 3) the homeodomain.
Fig. 3. Alternate transcripts of PAX3 produced by alternate splicing at
intron-exon boundaries. The predicted locations of translation
termination are indicated by an arrow for each transcript. PAX3a and
PAX3b: These transcripts lack the entire homeodomain and c-terminus
(Tsukamoto et al., 1994). PAX3c: Transcript containing 8 exons and a
stop codon 5 bp into intron 8 (Goulding et al., 1991). PAX3d: Transcript
contains exon 9 spliced directly onto the 3’ end of exon 8 (Barber et al.,
1999). PAX3e: Transcript containing 10 exons (Barber et al., 1999).
Pax3f: Transcript found in murine cDNA contains exon 9 directly spliced
to the 3’ end of exon 5 (Barber et al., 1999).
domain within the encoded proteins. 
PAX genes and cancer 
Mutations in PAX genes are associated with
development of a variety of cancers such as astrocytoma,
medullablastoma, lymphoplasmacytoid lymphoma,
Wilm’s tumour, melanoma, sarcoma, rhabdomyosarcoma
and thyroid cancer (Dressler and Douglas, 1992; Kozmik
et al., 1995; Stuart et al., 1995; Iida et al., 1996; Schulte
et al., 1997; Kelly et al., 1998; Barr et al., 1999;
Vachtenheim and Novotna, 1999; Kroll et al., 2000;
Scholl et al., 2001). 
Established associations of PAX genes with cancer
include chromosomal translocations that in turn encode
oncogenic fusion proteins. The PAX3-FKHR t(2;13) and
PAX7-FKHR t(1;13) translocations are responsible for
alveolar rhabdomyosarcoma (Bennicelli et al., 1996), the
PAX5 t(9;14) translocation plays a role in
lymphoplasmacytoid lymphoma (Iida et al., 1996) and
the PAX8-PPARd fusion oncoprotein in thyroid
carcinoma (Kroll et al., 2000). 
Although mutations in PAX genes are associated
with the many forms of cancer described above, this is
not the case in ERMS and CMM, where the causative
mutations are at gene loci other than those of the PAX
gene family. Of note, however are the recent findings by
Barr et al. (1999) showing increased and aberrant
expression profiles of PAX3 and PAX7 transcripts in
these tumours. These recent investigations were based
on the reasoning that expression of PAX genes in
myogenic and neural crest progenitors might be repeated
in tumour cells arising from the same lineage. Using
RNAse protection assays to quantify PAX3 and PAX7
expression in both cell lines and tumour tissue from
ERMS and CMM, levels of PAX3 and PAX7 in ERMS,
and PAX3 in CMM were found to be “notably high”.
In these cancers, the predominant PAX3 and PAX7
transcripts contain a previously uncharacterised ninth
exon (Fig. 4). Additional PAX3 and PAX7 transcripts
resulting from alternative splicing at exon 8 were also
observed (Barr et al., 1999). These findings raise the
possibility that the metastatic phenotype of ERMS and
CMM may be specifically related to the increased,
aberrant expression of specific PAX transcripts. 
How would these transcripts play a role in tumour
metastasis? Aberrant PAX expression has been
demonstrated to affect activation of downstream target
genes associated with cell proliferation and adhesion. In
CMM, altered PAX3 expression is consistently
associated with loss of expression of the Mitf gene and
subsequent proliferation leading to melanoma formation
(Galibert et al., 1999; Vachtenheim and Novotna, 1999;
Kamaraju et al., 2002). Mitf is essential for melanocyte
differentiation and plays a role in the regulation of genes
required for melanogenesis (Bentley et al., 1994;
Yasumoto et al., 1997). 
Moreover, aberrant PAX3 expression has been
correlated with up-regulation of ST8SiaII/STX, a gene
involved in the post-translational sialylation of NCAM.
Increased NCAM sialylation results in decreased cell
adhesion and increased cell migratory properties.
(Mayanil et al., 2000). 
The ability of PAX genes to affect cell surface
molecules involved in regulation of cell motility and
adhesion has important implications for metastasis. We
next review PAX gene regulation of cell surface
molecules, particularly those involved in delamination,
migration and adhesion during embryogenesis, as they
provide interesting links to metastatic capabilities.
Cell surface molecules associated with migration
Eph receptors and ephrins
Important biochemical cellular surface molecules
that function in the migration of embryonal cells are
ephrin ligands and their cognate family of Eph receptors.
Eph/ephrin complexes regulate morphogenesis of the
embryo by affecting the adhesive and/or repulsive
properties of the migrating cell. 
The Eph receptor family of tyrosine kinases consists
of at least fourteen receptors and nine ligands (Eph
Nomenclature Committee, 1997). Class A receptors bind
to GPI-anchored ligands whereas class B receptors bind
to transmembrane ligands; EphA4 is the only receptor
with an affinity for both classes of A and B ligands (Gale
et al., 1996).
Mechanisms of Eph receptor/Ephrin induced migration
Induction of either a repulsive or attractive signal in
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Fig. 4. Diagram indicating alternative PAX3 and PAX7 transcripts found
expressed in ERMS and CMM relative to normal tissue. The transcribed
3’ regions of the genes are shown as closed boxes and attached
horizontal lines, respectively. The paired box is designated PB, the
homeodomain is designated HD and exons are labelled with dashed
vertical lines. A) PAX3 and C) PAX7 cDNA transcripts found in normal
tissue containing exons 1-8. B) Predominant PAX3 and D) predominant
PAX7 transcripts found expressed in ERMS (PAX3 and PAX7) and
CMM (PAX3). The dark area indicates the position at which the
alternately spliced exon 9 is attached to an alternative 3’ splice site in
exon 8 (adapted from Barr et al., 1999) 
the cell cytoplasm is achieved by activation of protein
tyrosine kinases that catalyse tyrosine phosphorylation
of substrate proteins (Wybenga-Groot et al., 2001). Eph
receptor mediated repulsion functions through an
intricate system of initial binding, cleavage by a
metalloprotease, shedding of the ephrin ectodomain and
subsequent cell retraction or detachment and movement
(Krull, 1998; Hattori et al., 2000). Alternatively,
resistance to proteolysis may transduce adhesive signals
to the cytoplasm. Class A ephrins containing shorter
membrane regions (Lai et al., 1999) become resistant to
metalloproteases due to inaccessibility of the protease to
the proximal region of the ligand (Schlondorff and
Blobel, 1999). 
Recently, Honda and Mochizuki (2002) proposed a
bilateral threshold control mechanism to explain
Eph/ephrin mediated cellular repulsion or adhesion; cells
adhere to each other if their surfaces bear a critical
density of ligand which is reciprocal to the density of the
receptor, whereas, cells are repelled if the density of
ligands is unequal to the critical threshold. 
Eph receptors and ephrins in embryogenesis
There is much evidence to support a role for
Eph/ephrin complexes in mediation of cell movement
during embryonic pattering, axonal pathfinding, vascular
development and angiogenesis (Iwamasa et al., 1999;
Marin et al., 2001; for review see Cheng et al., 2002;
Coulthard et al., 2002). 
Of particular interest to our study are the situations
in the developing embryo where Eph/ephrin mediated
repulsion results in de-adhesion, collapse of cell
processes and cell detachment. It has been observed that
Eph/ephrin binding results in cleavage and shedding of
the ephrin ectodomain allowing cell detachment to occur
(Krull, 1998; Hattori et al., 2000). This process of
collapse and retraction has been observed in developing
axons (Oakley et al., 1993) and individual cells of the
migrating neural crest (Krull, 1998). Collapse and
retraction of cells due to Eph/ephrin signalling may be
comparable to the detachment of the metastatic cell from
a primary tumour.
It is possible that the adhesive role of Eph/ephrin
signalling also has implications in metastasis. During
embryogenesis, Eph/ephrins induced cell adhesion is
important for digit formation (Staedler et al., 2001),
closure of the neural tube (Holmberg et al., 2001) as well
as angiogenesis (Pandey et al., 1995). In angiogenesis,
Eph/ephrin signalling activates cell adhesion to
extracellular matrices via integrin-dependent
mechanisms (Huyn-Do et al., 1999; Miao et al., 2000).
The endothelium of blood vessels contains a
physical barrier that metastatic cells must penetrate in
order to invade the underlying tissue. Thus, the presence
of Eph receptors and ephrins, located on both endothelial
cells of vascular vessels and disseminated tumour cells,
may be an important part of the mechanism by which
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Fig. 5. Immunohistochemistry to
detect downstream target genes of
Pax 7. P19 cells, transfected with a
PAX7-pHM6 vector construct or with
pHM6 vector alone, were fixed in 4%
paraformaldehyde and gene
expression was assessed using Pax7
and ephrin-A2 antibodies. A. Positive
PAX7 expression was observed in the
nuclei of P19 cells transfected with
PAX7 but was not observed in B,
undifferentiated cells transfected with
pHM6 vector. C. Ephrin-A2
expression was observed in P19 cells
transfected with PAX7 but no ephrin
expression was present in D pHM6
vector transfected cells. Scale bar:
20 µm. Similar results were obtained
in three experiments performed in
three or more separate clones. (From
Thomas et al., 2001).
tumour cells pass through the endothelial junction, thus
increasing the metastatic cell’s ability to extravasate.  
Pax genes and regulation of Eph receptors and
ephrins
Studies in our laboratory as well as others,
demonstrate a close association between Pax gene and
Eph/ephrin expression. Pax7 and ephrin-A2 co-localise
in spatiotemporal patterns to neurones of the superficial
layers of the superior colliculus (Kawakami et al., 1997;
Marin et al., 2001) and a recent study performed in our
laboratory demonstrated that cells transfected with PAX7
in vitro consistently up-regulated ephrin-A2 (Thomas et
al., 2001) (Fig. 5). 
In a similar manner, the EphA4 receptor is thought
to play a role in migration of Pax7 expressing muscle
precursor cells to the limb bud during embryonic
development (Swartz et al., 2001), while Pax6 is thought
to regulate EphB2 expression in retinal ganglion cell
neurons (Ziman et al., 2003). Thus the ability of PAX
genes to up-regulate the Eph receptors and ephrins may
play a role in developmental migration of neural crest
and myogenic cells along clearly defined paths. 
Eph receptors, ephrins and cancer
Considering the importance of ephrins and Eph
receptors in normal cell signalling, adhesion and
migration it is highly probable that they are key
determinants in the metastatic process. In fact, numerous
reports detail the over-expression of Eph receptors, such
as EphA2, EphA3 and EphB2 in various tumour types
including melanomas (Easty and Bennett, 2000;
Lawrenson et al., 2002), sarcomas (Chiari et al., 2000),
small cell lung cancer (Tang et al., 1999) and breast
cancer (Nikolova et al., 1998). Not surprisingly, higher
expression levels of Eph receptors are found to correlate
with more malignant and metastatic tumours (Easty et
al., 1995; Zelinski et al., 2001). 
EphA2 is consistently over-expressed in 90% of
metastatic melanoma cell lines (Easty et al., 1999)
whereas EphA2 expression is not detected in normal
melanocytes (Easty and Bennett, 2000). Coincidently,
Scholl et al. (2001) reported that PAX3 expression is
similarly confined to malignant metastases with no PAX3
expression in the surrounding normal tissue or benign
nevi. 
These results imply that up-regulation of PAX genes
in metastatic cells may in turn activate expression of Eph
receptors and ephrins thereby increasing the ability of
the cell to migrate in a manner similar to that of
embryonic cells. Further research to establish a link
between PAX genes and Eph/ephrins in metastatic
tumours is currently being performed in our laboratory.
Neural cell adhesion molecules
Another important cell surface molecule that is
crucial for cell migration of embryonal cells is the neural
cell adhesion molecule (NCAM). Of particular
significance to the present study is its previously
identified role as a downstream target of several Pax
genes (Edelman and Jones, 1995; Wang et al., 1996;
Holst et al., 1997).
Definition, structure and function
The neural cell adhesion molecule (NCAM) is
classified as a member of the immunoglobulin
superfamily (Edelman and Crossin, 1991); it functions in
morphogenic patterning through the mediation of
homophilic or heterophilic binding between cells.
NCAMs span the cellular membrane, have a short
cytoplasmic tail and contain five Ig-like repeats that are
expressed on the extracellular domain of the protein
(Springer, 1990). 
NCAM exists as several isoforms- 120-kDA, 140-
kDA and 180-kDA (Cunningham et al., 1987; Roesler et
al., 1997; Perl et al., 1999). NCAM-120 contains a
unique exon; when included in the transcripts, this exon
encodes a plasma membrane GPI anchor (Roesler et al.,
1997). NCAM-140 and NCAM-180 contain trans-
membrane components encoded by an additional exon.
The 180-kDA isoform occurs predominantly on
differentiated cells interacting with spectrin to bring
about cellular adhesion to the basal lamina or to adjacent
cells (Roesler et al, 1997). 
Polysialylation of NCAM
A post-translational modification of NCAM that
directly affects its adhesive properties is polysialylation.
Polysialic acid is a large negatively charged
homopolymer and its linkage to NCAM negates the
kinetics of homophilic dimerisation promoting
heterophilic binding of NCAM to extracellular matrix
proteoglycans (Rutihauser et al., 1988; Storms and
Rutihauser, 1998). 
The polysialylated form of NCAM (PSA-NCAM) is
expressed in a large variety of tissues in the embryo and
is associated with increased cellular mobility. As the
brain develops, PSA-NCAM augments cellular motility,
assisting neuron outgrowth. Conversely, PSA-NCAM is
not present within the adult brain other than in areas
requiring synaptic regrowth such as the hippocampus
and olfactory bulb (Tanaka et al., 2000). 
PAX proteins and regulation of NCAM
The NCAM gene contains a binding site for the
paired domain of Pax (PBS) (Holst et al., 1997) and two
homeodomain binding sites (HBS) (Wang et al., 1996).
Pax proteins are thought to regulate NCAM expression
via the PBS and HBS sequences in its promoter. The
PBS promotor region of NCAM consists of two half sites
that are identical to the consensus binding sequences of
various Pax proteins (Wang et al., 1996). Moreover,
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Pax3 has been shown to regulate NCAM expression by
binding at PBS half sites (Chelapakis et al., 1994).
NCAM and Cancer
The importance of NCAM in conferring oncogenic
properties to a neoplasm is highlighted by studies that
show tumours lacking the 180-kDa isoform demonstrate
clinically aggressive behaviour that is associated with
metastatic disease or patient death within 18 months of
presentation. The presence of the 180-kDA isoform of
NCAM in tumours is associated with non-aggressive
clinical behaviour (Roesler et al., 1997).
Furthermore, although PSA-NCAM expression is no
longer present in most adult tissues, re-expression of the
polysialylated form of NCAM has been demonstrated in
malignant tumours such as small-cell lung cancer,
neuroblastoma, alveolar rhabdomyosarcoma and
medullablastoma (Soler et al., 1993; Kojima et al., 1997;
Gluer et al., 1998a,b; Mayanil et al., 2000; Tanaka et al.,
2000). 
Of particular interest to this study is the fact that
mutation of PAX genes results in increased expression of
polysialylated NCAM (Fukuda et al., 2000). In a study
of medullablastoma, increased presence of polysialylated
NCAM was associated with an increased expression of
the STX gene which was further attributed to an over-
expression of PAX3 (Mayanil et al., 2001). These results
indicate that aberrant expression of PAX genes may
affect NCAM and PSA-NCAM expression and in turn
affect metastatic potential.
Conclusion
ERMS and CMM have the propensity to be more
dangerous than several other forms of cancer due to their
ability to invade surrounding tissues and metastasise
early in their development. Generally, about 50% of
patients have metastatic spread at the time of clinical
detection (DeVita et al., 1975).
Clinical research and animal studies have shown that
metastasis is an event that reflects the properties of both
the host tissues and the metastatic cell itself (for review,
see Fidler, 1978). The ability of a cancer cell to take
advantage of genetic programs set in place specifically
for normal cellular functions such as cell detachment,
migration and adhesion, could give the metastatic cell a
tremendous selective advantage. 
Future work in the study of the cancer cell
phenotype would benefit by assessing expression of
genes important for embryonal patterning and migration.
Developmental control genes such as the PAX family of
genes may hold keys to the understanding of oncogenic
events such as (and not limited to) metastasis. As we
continue to uncover the cellular events that take place
during the transformation of the undifferentiated stem
cell to the terminally differentiated adult cell, we
continue to discover key players that may propagate
metastatic cell behaviour. 
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